Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.

Journal: Breast (Edinburgh, Scotland) •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Li J, Han X, Zhuang Y, et al. (2026). "Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.". Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104906